Program
Current as of Friday 29 July 2026, and is subject to change.
The AMC 2026 program features a broad range of speakers across multiple disciplines and concurrent sessions, organised under four key themes:
Prevention
Early Detection
Advanced Disease
Survivorship
How to read this program
Plenary
Concurrent
Panel Discussion
Late breaking
Break
Social event
Sponsored symposium
Oral abstract
Thursday 19 November · Day 1 · Pre-Conference
8:00 AM – 5:00 PM9 hrs
MASC Trials Scientific Meeting
Sofitel Melbourne on Collins
3:00 PM – 6:30 PM3.5 hrs
Registration for AMC 2026 Open
Sofitel Melbourne on Collins · Registration Desk
5:00 PM – 6:30 PM90 mins
Welcome Networking Reception
Sofitel Melbourne on Collins
Friday 20 November · Day 2 · Main Program
7:00 AM – 6:00 PM11 hrs
Registration Open
Sofitel Melbourne on Collins · Registration Desk
8:15 AM – 9:45 AM90 mins
Invited Speakers: Eugene Semenov, Vivek Naranbhai
9:45 AM – 11:15 AM90 mins
UK experience with AI-assisted triage
Invited SpeakerRubeta Matin
Imaging AI in Skin Cancer Practice
Invited SpeakerJohn Prossor
Legal and regulatory considerations when using AI in clinical practice
Invited SpeakerLisa Abbott
Using scribes in practice
Invited SpeakerSteve Salerno
AI: The Consumer/Patient Perspective
Invited SpeakerMonika Janda
Known and Unknown AI Gems
Invited SpeakerHarrison Edwards
Panel/audience Q&A (all speakers)
Invited Speakers: Eugene Semenov, Zaid Ardalan, Ming-Wei Lin
Polygenic risk for idiopathic Inflammatory Bowel Disease predicts severe colitis following Immune Checkpoint Blockade in advanced melanoma
Oral AbstractHadis Ghajari
Circulating Antibody Profiling Identifies Predictive Biomarkers of Outcome and irAEs in Melanoma
Oral AbstractJoanna Chan
9:30 – 9:35Achieving Equity for Patients
Chair: Olivia Cook
9:35 – 10:00Reducing barriers to care for rural patients
Expanding Access to Specialist Skin Cancer Care: Supporting Rural Patients and the Evolving Role of Skin Cancer Nurses
Invited SpeakerEmma Zurawel, Melissa Sheldon
Multidisciplinary team perspectives on specialist melanoma nurse role integration and system-level impact across a national program
Oral AbstractRebecca Johnson
RISE4SkinCancer program: Regionally Integrated Systems Enhancement for Skin Cancer
Invited SpeakerLeigh Kinsman
10:00 – 10:50When Treatment Becomes the Challenge: Severe Multisystem Immunotherapy Complications in Advanced Melanoma
Panel discussion — lead Andrew Haydon
Case Study
Panel DiscussionAndrew Haydon
Patient Video
Faecal Microbiota Transplantation (FMT) as a treatment for colitis
Panel DiscussionSteven Nicolaides
Diet Therapy for ICI Colitis, Exclusive Enteral Nutrition Project
Panel DiscussionJess Fitzpatrick
Complexities of Melanoma Nurse Management: Preparing the Workforce for Current and Emerging Therapies
Panel DiscussionDonna Milne
10:50 – 11:00Q & A
11:15 AM – 11:45 AM30 mins
Morning Tea & Poster Session 1
Exhibition Hall
Break
11:45 AM – 1:15 PM90 mins
Changing the advertising code one submission at a time
Invited SpeakerAnne Gately
What does it take to reach an audience with a media campaign in times of distraction
Invited SpeakerCamilla Hercus
How can art be used to communicate about melanoma (The spot)
Invited SpeakerTamara Dawson
Making UV Visible: The Sunburnt Car Project
Invited SpeakerJoanneke Maitz
Sun protection and TikTok
Invited SpeakerAlvin Chong
Panel Discussion
Panel DiscussionIntroduction: 10 things I hate about Melanoma overdiagnosis
Invited SpeakerTony Caccetta
Clinician perspectives for: Melanoma overdiagnosis
Invited SpeakerTony Caccetta
Managing overdiagnosis: lessons from Australia’s national cancer screening programs
Invited SpeakerVivienne Milch
It's just the price we pay? A Health Economic perspective on Melanoma Overdiagnosis
Invited SpeakerDan Lindsay
Melanoma? Now what? Consumer perspectives.
Invited SpeakerPeter Gourlay
Pathological Aspects of Overdiagnosis
Invited SpeakerLouise Jackett
Panel Discussion
Panel DiscussionPanellists: Tony Caccetta, Vivienne Milch, Dan Lindsay, Peter Gourlay & Louise Jackett
Environmentally stressed drug-naive melanoma cells share a molecular signature with drug-tolerant and drug-resistant cells
Invited SpeakerNikolas Hass
Evaluating Insulin-like Growth Factor Binding 2 (IGFBP2) as a Mediator of Metastasis and Therapeutic Vulnerability in Uveal Melanoma
Invited SpeakerVivian Chua
IFNɣ promotes progression of nodal disease in metastatic melanoma
Invited SpeakerThomas Gebhart
Spatial transcriptomics reveals distinct cellular niches of resistance to immune checkpoint blockade in melanoma
Oral AbstractXiaohang Fu
Identification of metabolic phenotypes associated with prognosis and therapeutic response in patients with melanoma (MetaMel Study)
Oral AbstractThomas Breakell
1:15 PM – 2:15 PM60 mins
Lunch
Exhibition Hall
Break
1:35 PM – 1:55 PM20 mins
Lunch Session
Sponsored by Canfield
Sponsored Symposium
2:15 PM – 3:45 PM90 mins
The molecular effects of indoor tanning
Invited SpeakerHunter Shain
Sunscreen labelling and what consumers understand
Invited SpeakerAnna Nicholson
Sunscreen and Vitamin D: results from the Sun-D Trial
Invited SpeakerRachel Neale
TBA - Molecular Causation
Invited SpeakerAmaya Viros
Public interest and media stories - CHOICE report and other sunscreen interest stories in the media
Invited SpeakerRachel Carbonell
Spectral composition of ambient ultraviolet radiation and melanoma incidence across Australia
Oral AbstractCatherine Olsen
Panel Discussion
Panel DiscussionChair: Craig Sinclair
Should we perform skin checks
Invited SpeakerLinda Martin, Mostafa Khalafalla
Margins for invasive melanoma
Invited SpeakerAlexander van Akooi, David Speakman
Selective lymph node resection vs total lymphadenectomy after neoadjuvant drug therapy
Invited SpeakerThomas Pennington, Michael Hughes
Adjuvant immunotherapy for sentinel node positive disease
Invited SpeakerLavinia Spain
Can less be more? Exploring consumer and clinician perspectives on deintensification in melanoma using digital democracy tools
Oral AbstractJennifer Soon
Mind the Gap: Impact of new labels on public perceptions and calculated risk of adverse outcomes after a melanoma in-situ diagnosis
Oral AbstractZhuohan Wu
RADICAL Trial: results, cosmetic, patient-reported outcomes, and health economic synthesis; what's next?
Oral AbstractPascale Guitera
AI-Derived Biomarkers from Whole Slide Imaging for Melanoma Prognostication
Invited SpeakerEugene Semenov
Precision diagnostics for early melanoma detection using spatial biology and AI-guided image analysis
Oral AbstractMitch Stark
Clinical and pathological characteristics of thin cutaneous melanomas with rapid recurrence
Oral AbstractPrachi Bhave
Single-cell transcriptomic analysis of melanoma sentinel lymph nodes following pre-operative propranolol in a placebo-controlled, randomised trial
Oral AbstractNicholas Muller
Early Detection of Melanoma Using Circulating Tumour-specific Antibodies
Oral AbstractTawany De Carvalho Gil
Development and validation of a deep learning model with enhanced explainability for interpreting melanocytic tumour pathologies
Oral AbstractNigel Maher
Final questions & closing remarks from co-chairs
3:45 PM – 4:15 PM30 mins
Afternoon Tea
Exhibition Hall
Break
4:15 PM – 5:15 PM60 mins
The evolution of skin cancer
Invited SpeakerHunter Shain
Talk title TBC
Invited SpeakerRachel Neale
5:15 PM – 6:00 PM45 mins
Panel Discussion
Panel DiscussionPanellists: Tiffany Cherry, Grace Brown & Peter Soyer
7:00 PM – late
Conference Dinner
Melbourne Cricket Ground (MCG)
Saturday 21 November · Day 3 · Main Program
7:00 AM – 8:00 AM60 mins
Updates in the clinical & translational management of Merkel Cell Carcinoma
Shahneen Sandhu, Jürgen Becker, Richard Tothill
7:30 AM – 4:00 PM8.5 hrs
Registration Open
Sofitel Melbourne on Collins · Registration Desk
8:30 AM – 10:30 AM120 mins
Sunscreen: the burning topic in 2026
Invited SpeakerRachel Neale
What could the future of skin checks look like (ACEMID, AI)
Invited SpeakerVictoria Mar
The landscape is changing rapidly with new medicines for melanoma and skin cancer. What's new and what's on the horizon?
Invited SpeakerGrant McArthur
Advocacy Workshop: Lived Experience is Expertise: Advocacy & Influence.
What does good advocacy look like? How can we use our lived experience to create change? How can you make your voice heard?
Invited SpeakerMelissa Sheldon, Peter Gourlay, Craig Lawn, Anne Gately
Invited Speakers: George Pratt, Hugh Roberts, Mostafa Khalafalla, Pascale Guitera, Alan Pham
Beyond Checkpoint Inhibitors: The Emerging Role of TIL Therapy in Melanoma
Invited SpeakerAdnan Khattak
Talk title TBC
Invited SpeakerDamien Kee
Developing the next generation of tumour-infiltrating lymphocyte therapies for melanoma
Invited SpeakerHannah Newnes
Talk title TBC
Invited SpeakerAnnabell Bachem
Immune Cell Dynamics and Outcomes in Neoadjuvant-Treated Stage III Melanoma
Oral AbstractTina Hieken
10:30 AM – 11:00 AM30 mins
Morning Tea & Poster Session 2
Exhibition Hall
Break
11:00 AM – 12:00 PM60 mins
Talk title TBC
Invited SpeakerAmaya Viros
Talk title TBC
Invited SpeakerJergen Becker
12:00 PM – 12:30 PM30 mins
Highest-ranked late-breaking abstract submissions
12:30 PM – 1:30 PM60 mins
Lunch
Exhibition Hall
Break
1:05 PM – 1:25 PM20 mins
RELATIVITY in the Real World: Real world outcomes with nivolumab and relatlimab in metastatic melanoma
Rachel Roberts-Thomson
1:30 PM – 3:30 PM120 mins
Update from the national targeted melanoma screening roadmap
Invited SpeakerAnne Cust
Modelling a potential screeing program
Invited SpeakerDan Lindsay
GP perspectives on a potential screening program
Invited SpeakerSolange Green
ACEMID cohort characteristics and excision outcomes
Invited SpeakerSimone Goldinger
Embedding skin cancer prevention in melanoma screening: SunSmart in ACEMID pilot results
Oral AbstractAnna Nicholson
Additional risk loci and a comprehensive polygenic risk score for melanoma from the largest GWAS to date: Towards melanoma risk based screening
Oral AbstractJayasinghe
Factors associated with a diagnosis of thick invasive melanoma: findings from the QSkin prospective cohort
Oral AbstractNirmala Pandeya
Panel Discussion
Panel DiscussionPanellist: Alison Button-Sloan
Cardiovascular Risk in Long-Term Melanoma Survivorship after Immunotherapy
Invited SpeakerSean Tan
The Role of Exercise in Patients Receiving Immunotherapy
Invited SpeakerEva Zopf
Beyond Survival: Caring for the Psychological Impact of Melanoma
Invited SpeakerClaire Gore
Towards Safe Discontinuation of Immune Checkpoint Inhibitor Therapy: Integrating Digital Pathology and Gene Profiling in Melanoma
Oral AbstractOana-Diana Persa
The melanoma school: safe and effective discharge of early-stage melanoma patients to community care
Oral AbstractEdward Clarke
MPA nurse-led survivorship service and role in providing survivorship care beyond the acute setting
Invited SpeakerPeta Holly
Panel Discussion
Panel DiscussionPanellists: Richard Kelly, Danielle Goss, Julie Teraci, Justin Tse, Karen van Gorp & Tamara Dawson
Mechanisms of tumorigenesis in acral melanoma
Invited SpeakerYeye Guo
Nail apparatus melanoma with comparison of biopsy technique
Invited SpeakerCliff Rosendahl
Ocular/periocular melanoma: histopathologic challenges
Invited SpeakerPenny McElvie
Periocular melanoma: Management challenges
Invited SpeakerAlex Chamberlain
Ocular melanoma: diagnostic and therapeutic challenges
Invited SpeakerRod O'Day
Ocular melanoma therapies and clinical trials
Invited SpeakerMal Ameratunga
Targeting Epigenetic Enzymes in Metastatic Uveal Melanoma
Oral AbstractJason Lee
3:45 PM – 4:30 PM45 mins
Talk title TBC
Invited SpeakerGeorgina Long
Talk title TBC
Invited SpeakerAdnan Khattak
4:30 PM – 4:45 PM15 mins
Closing Remarks
Sofitel Melbourne on Collins